Hefei Chuandi Pharmaceutical Technology

Hefei Chuandi Pharmaceutical Technology is a clinical-stage biotechnology company based in Hefei, China, dedicated to the discovery and development of innovative targeted protein degraders. The company utilizes its proprietary Proteolysis Targeting Chimera (PROTAC) platform to create small molecule therapeutics that selectively degrade disease-linked proteins. Its primary therapeutic focus lies in oncology and autoimmune diseases, where it aims to address limitations of traditional occupancy-based inhibitors. The lead candidate, CD-001, is an orally available androgen receptor (AR) degrader currently undergoing Phase 1 clinical trials for the treatment of metastatic castration-resistant prostate cancer. Founded by industry veterans with extensive experience in global drug development, Chuandi is supported by prominent regional investors. The company's pipeline includes several other protein degradation programs in the discovery and pre-clinical stages targeting high-value oncogenic drivers.